As of 2026-03-12, the Relative Valuation of Apellis Pharmaceuticals Inc (APLS) is 5.82 USD. This relative valuation is based on P/E multiples. With the latest stock price at 19.33 USD, the upside of Apellis Pharmaceuticals Inc based on Relative Valuation is -69.9%.
The range of the Relative Valuation is 4.64 - 7.38 USD.
| Range | Selected | |
| Trailing P/E multiples | 26.2x - 31.5x | 28.8x |
| Forward P/E multiples | 23.5x - 30.4x | 27.0x |
| Fair Price | 4.64 - 7.38 | 5.82 |
| Upside | -76.0% - -61.8% | -69.9% |
| Date | P/E |
| 2026-03-09 | 112.98 |
| 2026-03-06 | 113.43 |
| 2026-03-05 | 113.88 |
| 2026-03-04 | 112.24 |
| 2026-03-03 | 113.94 |
| 2026-03-02 | 116.99 |
| 2026-02-27 | 118.46 |
| 2026-02-26 | 122.30 |
| 2026-02-25 | 121.06 |
| 2026-02-24 | 125.07 |
| 2026-02-23 | 126.99 |
| 2026-02-20 | 125.92 |
| 2026-02-19 | 128.86 |
| 2026-02-18 | 125.47 |
| 2026-02-17 | 121.91 |
| 2026-02-13 | 122.64 |
| 2026-02-12 | 124.62 |
| 2026-02-11 | 126.09 |
| 2026-02-10 | 127.62 |
| 2026-02-09 | 129.03 |
| 2026-02-06 | 132.76 |
| 2026-02-05 | 127.50 |
| 2026-02-04 | 130.84 |
| 2026-02-03 | 131.80 |
| 2026-02-02 | 129.03 |
| 2026-01-30 | 127.62 |
| 2026-01-29 | 130.27 |
| 2026-01-28 | 130.38 |
| 2026-01-27 | 123.26 |
| 2026-01-26 | 124.28 |
| 2026-01-23 | 122.92 |
| 2026-01-22 | 124.34 |
| 2026-01-21 | 118.40 |
| 2026-01-20 | 115.69 |
| 2026-01-16 | 112.69 |
| 2026-01-15 | 116.03 |
| 2026-01-14 | 114.90 |
| 2026-01-13 | 120.55 |
| 2026-01-12 | 131.12 |
| 2026-01-09 | 154.29 |
| 2026-01-08 | 148.41 |
| 2026-01-07 | 149.71 |
| 2026-01-06 | 135.30 |
| 2026-01-05 | 140.56 |
| 2026-01-02 | 146.15 |
| 2025-12-31 | 141.97 |
| 2025-12-30 | 142.65 |
| 2025-12-29 | 142.25 |
| 2025-12-26 | 141.12 |
| 2025-12-24 | 142.20 |